A collection of photos showcasing the Pathfinders Hall of Fame from 2005 to 2021.
In this issue, The HQ focuses on the continuously emerging COVID-19 variants. As mutations continue to arise and the spread of the virus is still prevalent, vaccine roll-outs with desired herd immunity to end the pandemic is still far from sight. Esco anticipates the need for scale-up solutions in providing leading-edge technologies to support stakeholders in producing top-of-the-line quality vaccines.
Several variants of the SARS-CoV-2 have been observed in recent researches. Data regarding their characteristics became widely available, interlinking them with a higher rate of transmissibility and a higher rate of evading the host immune response. These attributes make these variants even more challenging to control. While most emerging mutations will not have a significant impact on the spread of the virus, the news of them appearing still invoked fear within the public.
COVID-19 vaccines are generally concurred to be the most effective in sustainably controlling the pandemic. It is after all proven that while countermeasures such as social distancing, universal face covering, and frequent handwashing are effective, it is not completely reliable and does not often work if disregarded. For that reason, the best way to avoid being infected by the virus is to be vaccinated.
